Chemokines are instrumental in macrophage-and T cell-dependent diseases. The chemokine CCL2 promotes kidney disease in two models of immune-mediated nephritis (MRL-Fas lpr mice and the nephrotoxic serum nephritis model), but evidence suggests that multiple chemokines are involved. For identification of additional therapeutic targets for immune-mediated nephritis, chemokine ligands and receptors in CCL2
pivotal in promoting renal disease in these models. Using CCL2 Ϫ/Ϫ MRL-Fas lpr mice, we established that tubular/interstitial and glomerular disease is suppressed. 10 By comparison, tubular/interstitial but not glomerular disease is suppressed in CCL2 Ϫ/Ϫ mice during NSN. 10, 11 In each model, Mø and T cells are no longer recruited to sites in the interstitium adjacent to tubular epithelial cells (TEC), the major source of CCL2 in WT mice with nephritis 10, 11 ; however, Mø and T cells remain in perivascular areas lacking CCL2 but rich in CCL5 (RANTES), a chemokine capable of inciting local renal inflammation in MRL-Fas lpr mice. 12 This suggests that multiple chemokines dictate the tempo and locale of kidney disease.
To identify the chemokines along with CCL2 that are instrumental in T cell-and Mø-mediated nephritis, we extensively profiled kidneys of CCL2 Ϫ/Ϫ and wild-type (WT) MRLFas lpr mice during the development of lupus nephritis. We identified a highly expressed chemokine ligand/receptor pair instrumental in attracting T cells during inflammation, CXCL10 (IP-10)/CXCR3. [13] [14] [15] [16] We report that CXCR3 is expressed on intrarenal activated Mø in addition to T cells during experimental immune-mediated kidney disease. Furthermore, the expression of CXCR3 on T cells and Mø seems to mediate their recruitment into the kidneys expressing CXCL9 during NSN. Finally, we determined that CXCR3 and one, CXCL9, but not another, CXCL10, of its ligands promote T cell-and Mø-dependent nephritis. Thus, CXCL9 and CXCR3 are potential therapeutic targets for immune-mediated kidney illnesses.
RESULTS

Multiple Chemokine Ligand/Receptors Are Upregulated in MRL-Fas lpr Nephritic Kidneys
To identify potential therapeutic chemokine ligand/receptor targets in MRL-Fas lpr mice, we compared intrarenal chemokine ligand/receptor transcripts in mice before (2 mo of age) and after (5 mo of age) onset of nephritis. The majority of intrarenal chemokine ligands (18 of 23) and chemokine receptors (10 of 16) we evaluated increased with advancing nephritis (Supplemental Figure 1) . We focused on the groups with the highest increase in intrarenal transcript expression. Within this group of chemokine ligands, we detected an increase in CXCL10 (nine-fold), CXCL9 (45-fold), CXCL11 (10-fold), CXCL13 (133-fold), CCL5 (16-fold), CCL20 (seven-fold), and CX3CL1 (two-fold), and within the group of chemokine receptors, we detected an increase in CXCR3 (nine-fold), CXCR4 (six-fold), CXCR5 (42-fold), CCR2 (10-fold), and CX 3 CR1 (six-fold; Supplemental Figure 1 ). Of note, the chemokine ligand/receptor transcript levels in the MRL-Fas lpr and B6 kidneys at 2 mo of age were similar.
Identifying Chemokine Ligand/Receptors Other than CCL2 that Are Expressed in Nephritic MRL-Fas lpr Kidneys CCL2 promotes lupus nephritis in MRL-Fas lpr mice. 10 To identify chemokines other than CLL2 that are central to MRLFas lpr nephritis, we compared chemokine ligand/receptor transcripts in CCL2
Ϫ/Ϫ and WT MRL-Fas lpr kidneys. Most (Ͼ80%) chemokine ligand/receptor transcripts that were upregulated in WT MRL-Fas lpr nephritic kidneys were suppressed in CCL2
Ϫ/Ϫ MRL-Fas lpr kidneys (Supplemental Figure  2) . One possible interpretation is that within the hierarchical pattern of chemokine ligand/receptor expression regulating immune responses, CCL2 is proximal in the chemokine cascade leading to nephritis in MRL-Fas lpr mice; therefore, our goal was to focus on the chemokine ligand/receptors that maybe expressed "downstream" of CCL2 in MRL-Fas lpr kidneys during nephritis. CXCL10 engaging with its receptor CXCR3 is a potent T cell chemoattractant. 15 Because CXCL10 is among the most highly upregulated chemokines and may be downstream of CCL2, we explored the role of CXCL10 in MRL-Fas lpr mice. Alveolar Mø express CXCL10, 17 and TEC are a rich source of multiple chemokines in MRL-Fas lpr mice 10 ; therefore, Mø and TEC were prime candidates in our attempt to identify sources of CXCL10. We detected CXCL10 in TEC ( Figure 1A ), leukocytes ( Figure 1A, To determine whether CXCL10 is central to lupus nephritis and the systemic illness, we compared CXCL10 Ϫ/Ϫ and WT MRL-Fas lpr strains (6 mo of age). The severity of glomerular, interstitial, and perivascular pathology was similar in CXCL10 Ϫ/Ϫ and WT MRL-Fas lpr mice ( Figure 1C ). Similarly, we did not detect a difference in the number (CD68 Figure 2C ) and CD11b ϩ (data not shown) after stimulation with LPS ( Figure 2C ) and IFN-␥ (data not shown) in WT mice. The specificity of CXCR3 Ab was verified by using CXCR3 Ϫ/Ϫ BMMø and an isotype control. Because activated Mø induce apoptosis of renal parenchymal cells, 11 we evaluated the frequency of activated Mø during NSN. Intrarenal CXCR3 ϩ -activated Mø increased during NSN as compared with untreated mice ( Figure 2D ). Thus, intrarenal CXCR3
ϩ -activated Mø and T cells are upregulated during NSN.
We next determined the intrarenal locale of the ligands (CXCL9, CXCL10) binding to CXCR3 during NSN. Because there is a functional loss of CXCL11 protein as a result of a missense mutation at 36 bp (G/A) and a single-nucleotide deletion mutation at 39 bp (C/Ϫ) in the gene for CXCL11 in B6 mice (Genbank sequence accession no. NT_109320; A.D.L. et al., unpublished observations), we evaluated CXCL9 and CXCL10. CXCL9 is expressed on the majority of TEC and absent on CXCL9 Ϫ/Ϫ kidneys during NSN and in untreated mice ( Figure 2E ). In addition, a small population of leukocytes express CXCL9 ( Figure 2E ). These intrarenal CXCL9 ϩ leukocytes that increased during NSN are CD4 ϩ and CD68 ϩ cells ( Figure 2E ). Similarly, CXCL10 is expressed primarily on TEC and to a lesser extent on leukocytes and is absent in CXCL10
Ϫ/Ϫ control kidneys during NSN and in untreated mice ( Figure 2E ). The increase in intrarenal CXCL10
ϩ leukocytes during NSN is in CD4 somewhat higher than in CXCL9 ϩ cells, it was substantially (Ͼ2ϫ) lower than in CXCR3 ϩ cells ( Figure 2 , B and E). Thus, intrarenal CXCR3 is primarily expressed on activated T cells and Mø, whereas the ligands CXCL9 and CXCL10 are largely generated by TEC during NSN. Of note, CXCL9 and CXCL10 expression and CXCR3
ϩ leukocytes are rarely detected in glomeruli , and CXCL10 Ϫ/Ϫ mouse strains do not express a functional CXCL11, for simplicity, we refer to each strain as the single unique "knockout." CXCR3 Ϫ/Ϫ mice were protected from the loss of renal function ( Figure 3A) . By comparison, renal function in CXCL10 Ϫ/Ϫ mice was similar to WT mice during NSN ( Figure 3A) . Consistent with preserving renal function, renal pathology in CXCR3 Ϫ/Ϫ but not in CXCL10 Ϫ/Ϫ mice was reduced ( Figure 3B ). Tubular and glomerular pathology were blunted in CXCR3 Ϫ/Ϫ but not in CXCL10 Ϫ/Ϫ mice. Thus, CXCR3 but not CXCL10 promotes NSN, suggesting that another CXCR3 ligand is instrumental in immune-mediated nephritis.
To determine whether CXCL9, another ligand for CXCR3, promotes immune-mediated nephritis, we compared
CXCL9
Ϫ/Ϫ and WT mice during NSN. Renal function (proteinuria, blood urea nitrogen, and serum creatinine) was improved in CXCL9 Ϫ/Ϫ mice ( Figure 3A) . Similarly, renal pathology (glomerular and tubular) was suppressed in CXCL9 Ϫ/Ϫ mice ( Figure 3B , Supplemental Figure 3) . Notably, renal function ( Figure 3A ) and pathology (data not shown) in CXCR3 Ϫ/Ϫ and CXCL9 Ϫ/Ϫ mice did not return to baseline (untreated mice). This suggests that CXCR3 and one, CXCL9, We detected a decrease in serum total anti-sheep IgG and IgG1 (n ϭ 6/group) and glomerular IgG deposits (n ϭ 4/group) in CXCR3 Ϫ/Ϫ compared with WT mice. Similarly, we detected a reduction in serum total anti-rabbit IgG and IgG1 (n ϭ 7 to 8/group) and in glomerular IgG deposits (n ϭ 4/group) in CXCL9 Ϫ/Ϫ compared with WT mice. In contrast, serum anti-sheep IgG isotypes (n ϭ 6/group) and IgG glomerular deposits (n ϭ 4/group) in CXCL10 Ϫ/Ϫ mice did not differ from WT mice. Data are means Ϯ SEM. ϩ , CD8 ϩ , and Mø were detected in the glomeruli (intra-, periglomerular) and interstitium in CXCR3 Ϫ/Ϫ mice ( Figure 4A) . A similar decrease in CD4 ϩ T cells and Mø occurred in the CXCL9 Ϫ/Ϫ kidneys, whereas we did not detect a reduction in these leukocytic populations in CXCL10
Ϫ/Ϫ mice (data not shown).
CXCR3 is expressed on activated T cells 19 and Mø; therefore, we compared these intrarenal leukocytes in CXCR3 Ϫ/Ϫ mice with WT mice during NSN. We detected a decreased frequency of activated (CD69 ϩ ) CD4 ϩ and CD8 ϩ T cells and activated (CD86 ϩ ) Mø in CXCR3 Ϫ/Ϫ mice during NSN (Figure 4B) . In support of this decrease in activated Mø, the frequency of TNF-␣ ϩ Mø was diminished ( Figure 4C , circled, immunofluorescence). Similarly, CXCL9
Ϫ/Ϫ mice had a reduced frequency of activated T cells and Mø ( Figure 4B) 20, 21 ; therefore, we determined whether the attenuated severity of kidney disease in CXCR3 Ϫ/Ϫ and CXCL9 Ϫ/Ϫ mice was related to a reduction in circulating levels of antigen-specific IgG isotypes during NSN. For this purpose, we measured the antisheep and -rabbit IgG isotypes in the sera of CXCR3 Ϫ/Ϫ and CXCL9 Ϫ/Ϫ mice, respectively, in comparison with WT mice during NSN. We detected a suppression of IgG and IgG1 and not IgG2b at multiple titers (2.0 to 8.0 ϫ 10
) in CXCR3
Ϫ/Ϫ and CXCL9 Ϫ/Ϫ mice ( Figure 5A ). Because serum isotypes were attenuated in CXCR3 Ϫ/Ϫ and CXL9 Ϫ/Ϫ mice, we hypothesized that the reduced renal pathology resulted from decreased deposition of IgG within glomeruli of CXCR3 Ϫ/Ϫ and CXCL9 Ϫ/Ϫ mice. We detected a reduction in IgG deposits at multiple dilutions (3.0 to 7.5 ϫ 10
Ϫ/Ϫ and CXCL9 Ϫ/Ϫ glomeruli ( Figure 5B ).
Contrastingly, circulating anti-sheep IgG isotypes and glomerular IgG deposits in CXCL10
Ϫ/Ϫ did not differ from WT mice. Taken together, this suggests CXCR3 engaging with CXCL9 may promote renal disease by increasing systemic IgG and IgG deposits within glomeruli.
DISCUSSION
Chemokines are tempting therapeutic targets for a wide range of diseases, because they are specifically upregulated during inflammation. Mø and T cells are instrumental in mediating renal inflammation; thus, chemokines that regulate Mø and T cells within the kidney are potential therapeutic targets for nephritis. Therefore, we extensively profiled MRL-Fas lpr kidneys before and during Mø-and T cell-dependent lupus nephritis. Although previous reports claimed that a few chemokine ligands (four of nine) and chemokine receptors (three of six) are upregulated in MRL-Fas lpr kidneys, we now report that the majority of chemokine ligands (18 of 23) and chemokine receptors (10 of 16) that we profiled were upregulated in MRLFas lpr mice with lupus nephritis. 6, 22 This difference in our findings may be related to the larger panel of chemokine ligand/ receptors in our experiments and the detection system (ribonuclease protection assay 22 versus real-time PCR, our study). We previously established that CCL2 is required to promote Mø-and T cell-dependent lupus nephritis in MRLFas lpr mice. 10 We now report that the rise in the panel of chemokine ligand/receptors that increase in MRL-Fas lpr mice is suppressed in CCL2 Ϫ/Ϫ MRL-Fas lpr mice. This may suggest that CCL2 is a "proximal master switch" in the chemokine cascade; however, increased expression of a specific chemokine during disease does not necessarily indicate that it promotes inflammation; it may not have an impact or even thwart inflammation. Therefore, we investigated the impact of CXCR3 and its ligands, CXCL9 and CXCL10, during Mø and T cell immune-mediated nephritis (NSN). Of note, we could not analyze the impact of CXCL11 during NSN because the protein for this remaining CXCR3 ligand is not expressed in B6 mice. We now report that CXCR3 and CXCL9 but not CXCL10 are central to Mø-and T cell-dependent kidney disease.
The impact of CXCL10 in autoimmune and kidney disease is controversial. Whereas Ab blockade of CXCL10 in experimental insulin-dependent diabetes 23 and adjuvant arthritis 24 abrogates disease, deleting CXCL10 does not diminish experimental autoimmune encephalomyelitis, although it lowers disease threshold. 25 Thus, the consequences of CXCL10 engaging with CXCR3 in autoimmune diseases are complex and yet not fully understood. Furthermore, the impact of CXCL10 on glomerular and tubulointerstitial renal disease is unclear. In induced forms of renal injury, puromycin aminonucleosideand anti-nephrin Ab-induced nephropathy, 26 Ab blockade of CXCL10 exacerbated proteinuria and podocyte injury. Conversely, Ab blockade of CXCL10 in a model of renal endothelial injury reduced interstitial T cell infiltration and improved renal function; however, pathology was not evaluated. 27 We now report that despite the abundant protein expression of intrarenal CXCL10 on TEC and leukocyte infiltrates, CXCL10 is not instrumental in two distinct models of immune-mediated renal disease, MRL-Fas lpr mice and NSN. This indicates that CXCL10 alone is not central to immune-mediated kidney disease.
Because it is possible that other ligands alone or together with CXCL10 promote immune-mediated kidney disease, we compared CXCR3
Ϫ/Ϫ and CXCL9 Ϫ/Ϫ mice during NSN with WT mice. CXCR3 and CXCL9 but not CXCL10 are central to immune-mediated kidney disease. This is the first report indi-cating that CXCL9 Ϫ/Ϫ mice are protected from nephritis. Our findings are in agreement with recent studies reporting that CXCR3 Ϫ/Ϫ mice develop less severe nephritis than WT mice during NSN. 28 In fact, CXCR3 has been shown to incite nonimmune-induced renal inflammation because CXCR3 orchestrates the recruitment of T cells instrumental in mediating renal ischemic injury. 16 Thus, CXCR3 may be a potential therapeutic target for a broad array of kidney diseases. Our findings are intriguing; although CXCL9 and CXCL10 protein expression is similar in locale and intensity during NSN, the functional impact of these two CXCR3 ligands differ. This differential impact on nephritis may be related to distinct bioavailability of CXCL9 and CXCL10. The preferential contribution of one CXCR3 ligand to disease pathology has been seen in other inflammatory models of disease, such as CXCL10 in mouse hepatitis virus and Dengue virus encephalitis 29, 30 and CXCL9 in herpes simplex virus-1 ocular infection and cytomegalovirus infection. 31, 32 Regardless of the exact mechanisms, our findings indicate that selective blockade of CXCL9 and CXCR3 is a potential therapeutic strategy to combat immune-mediated renal diseases.
Although it is well appreciated that activated T cells express CXCR3, we now report that activated and resting Mø express CXCR3 during kidney disease. The frequency of intrarenal CD68 ϩ cells along with CD4 ϩ and CD8 ϩ T cells expressing CXCR3 increased during NSN. This rise in CXCR3
ϩ Mø in the kidney is consistent with studies reporting that a low percentage of CXCR3 ϩ monocytes in the normal circulation increases in patients with rheumatoid arthritis. 33 Furthermore, we determined that whereas some primary cultured BMMø express CXCR3, the frequency increases after IFN-␥ stimulation and is even more robust after LPS stimulation. This suggests that whereas low numbers of resting Mø express CXCR3, the increase in CXCR3
ϩ Mø is a reflection of a rise in activated Mø during renal inflammation. Consistent with this concept, the total number of intrarenal activated CXCR3
ϩ Mø increases during NSN as compared with untreated mice. Furthermore, CXCR3 is responsible for recruiting these activated Mø, because there is a decrease in intrarenal activated Mø, along with activated CD4 ϩ and CD8 ϩ T cells, in CXCR3 Ϫ/Ϫ during NSN. This suggests that activated Mø bearing CXCR3 are central to inducing renal injury, because activated Mø release mediators that initiate TEC apoptosis. 11 Thus, we provide the first evidence that CXCR3 is instrumental in recruiting activated Mø, as well as T cells, into the kidney, that are responsible for inciting renal injury.
Humoral and cell-driven immune mechanisms mediate kidney disease. 20 We investigated whether the suppression in renal disease in the CXCR3 Ϫ/Ϫ and CXCL9 Ϫ/Ϫ mice during NSN was related to a decrease in pathogenic Ab within the kidney. We detected a reduction in total serum antigen-specific IgG and IgG1 Ab in CXCR3 Ϫ/Ϫ and CXCL9 Ϫ/Ϫ mice during NSN. Our finding is reminiscent of reduced Ab against a bacterial pathogen (Francisella tularensis) in CXCL9 Ϫ/Ϫ mice 34 ; however, our data are not in agreement with the recent study of CXCR3 Ϫ/Ϫ mice, indicating that there is no difference in total mouse anti-sheep IgG or antisheep IgG1 during NSN (day 8). 28 This difference may be related to the assay methods, the day of analysis, or other variables related to inducing NSN. Nevertheless, our data support the concept that CXCR3 and CXCL9 enhance Ab production during immune responses. The regulation of serum IgG and glomerular deposits by CXCR3 and CXCL9 remains unclear. We speculate that distinct patterns of CXCR3 ϩ
CD4
ϩ T cells and CXCL9 expression in germinal centers during inflammation and/or the expression of CXCR3 on a subset of memory B cells and plasma cells may regulate serum IgG and, in turn, glomerular deposits. 35, 36 Notably, the decline in antigen-specific IgG in CXCR3 Ϫ/Ϫ and CXCL9
Ϫ/Ϫ serum correlates with diminished IgG deposits within glomeruli; therefore, suppressed renal pathology and improved renal function may, in part, result from a reduced intrarenal deposition of pathogenic Ab in CXCR3 Ϫ/Ϫ and CXCL9 Ϫ/Ϫ mice during NSN. In addition, we did not detect CXCL9 and CXCL10 expression and CXCR3
ϩ leukocytes in glomeruli of WT mice during NSN. Thus, the reduction in proteinuria in CXCR3
Ϫ/Ϫ and CXCL9 Ϫ/Ϫ mice during the later stages of NSN may be related to the suppression of humoral immune responses. This is consistent with findings indicating that although the generation of autologous murine IgG against the nephrotoxic Ab is not essential for disease initiation, it may contribute to sustaining renal dysfunction. 37 This may indicate that although CXCR3 and CXCL9 promote the initiation of NSN via cell-mediated events, their regulation of the production and deposition of pathogenic Ab may be responsible for sustaining immune-mediated renal disease.
In conclusion, CXCR3 and one, CXCL9, but not another, CXCL10, of its ligands mediate activated T cells and Mø recruitment into the kidney and enhance Ab deposition in glomeruli that may, in turn, promote immune-mediated kidney disease. This suggests that blocking CXCR3 and CXCL9 is a potential therapeutic target for human immune-mediated kidney diseases.
CONCISE METHODS
Mice
We purchased MRL/MpJ-Fas lpr /Fas lpr (MRL-Fas lpr ) and C57BL/6 (B6) from the Jackson Laboratory (Bar Harbor, ME). Mice were housed and bred in our pathogen-free animal facility. CXCL9 null ( Ϫ/Ϫ ), CXCL10
Ϫ/Ϫ , CXCR3 Ϫ/Ϫ (B6 background), and CCL2
Ϫ/Ϫ (MRL-Fas lpr background) mice were generated as described previously. 4, 10, 34, 38 We generated CXCL10 Ϫ/Ϫ MRL-Fas lpr mice using a backcross-intercross scheme. MRL-Fas lpr mice were mated with CXCL10 Ϫ/Ϫ (B6 background) mice to yield heterozygous F1 offspring. We intercrossed F1 mice and screened the progeny for disrupted and intact CXCL10 and the Fas lpr mutation in tail genomic DNA. The DNA was assessed by PCR using oligonucleotide primers that recognized the normal CXCL10 gene: Sense (5Ј-TCC CTC CCG TAA CCA CAC AGT AAA T-3Ј) and antisense (5Ј-GCG GAT AGA CTC TGC TTT CAC TTT GG-3Ј) and Neo gene sense (5Ј-TGG ATG TGG AAT GTG TGC GAG-3Ј) and antisense (5-TTT CAC TTT GG-3Ј). Gel analysis of the PCR products identified the CXCL10 and Neo gene fragments at 342 and 640 bp, respectively. The Fas lpr mutation was identified as previously reported. 39 After five generations of backcross matings (N5), we analyzed and compared CXCL10 Ϫ/Ϫ MRLFas lpr mice with age-and gender-matched WT MRL-Fas lpr littermates. The number of mice analyzed is specified in each figure. We compared these strains at the N5 generation, because we previously established that there are sufficient MRL-Fas lpr background genes to result in consistent phenotypic changes characteristic of MRL-Fas lpr mice. 40 Use of mice in our study was reviewed and approved by the Standing Committee on Animals in the Harvard Medical School in adherence to the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Inducing NSN
We prepared nephrotoxic serum by immunizing sheep with a particulate fraction of mouse glomerular basement membrane from B6 mice kidneys, as described previously. 41 To induce NSN, we primed CXCL10 Ϫ/Ϫ , CXCR3 Ϫ/Ϫ , and WT male mice (6 wk of age) by injecting 0.5 mg of sheep IgG in Freund's complete adjuvant (Sigma Chemical Co., St. Louis, MO) subcutaneously in each flank. We challenged these mice 7 d later with an intravenous injection of nephrotoxic serum (15 l/g body wt). We used nephrotoxic serum from rabbits to immunize CXCL9 Ϫ/Ϫ and WT mice as described previously. 42 Mice were killed 14 d after challenge and analyzed. The number of mice in each group is specified within each figure.
Intrarenal Chemokine and Chemokine Receptor Transcripts
We analyzed the expression of chemokines (CXCL10, CXCL9, CXCL11, CXCL12, CCL13, CCL5, CCL28, CCL22, CCL24, CCL1, CCL17, CX3CL1, CCL25, CCL2, CCL8, CCL7, CCL3, CXCL2, CCL28␣, CCL4, CCL28␤, CCL27, CCL21, CXCL16, and CXCL1) and chemokine receptors (CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, and CX 3 CR1) in MRL-Fas lpr mice by using real-time, twostep, quantitative PCR, as described previously. 43 Primers were designed, as previously reported. 44 To detect CXCL10 expression during NSN, we used primers designed by Applied Biosystems (Foster City, CA). To detect CXCL9, CXCL11, and CXCR3 expression during NSN, we used the following primers: glyceraldehyde-3-phosphate dehydrogenase sense 5Ј-CAT GGC CTC CAA GGA GTA AG-3Ј and antisense 5Ј-CCT AGG CCC CTC CTG TTA TT-3Ј; CXCL9 sense 5Ј-TCC TTT TGG GCA TCA TCT TC-3Ј and antisense 5Ј-TTC CCC CTC TTT TGC TTT TT-3Ј; CXCL11 sense 5Ј-AGT AAC GGC TGC GAC AAA GT-3Ј and antisense 5Ј-GCA TGT TCC AAG ACA GCA GA-3Ј; and CXCR3 sense 5Ј-TGA GAC AAC TGA GGC CTC CTA-3Ј and antisense 5Ј-TCT TGC TCC CCA GTT GAT G-3Ј (Invitrogen, Carlsbad CA). We evaluated expression as previously reported. 45 
Isolation of TEC and BMMø
We isolated and cultured TEC from B6 and MRL-Fas lpr mice as previously reported, 46 and we isolated and cultured BMMø from B6 mice as described previously. 47 
Flow Cytometry
We prepared and stained single-cell suspensions from kidneys, spleens, or primary cultured TEC/BMMø as described previously. 48 We collected 0.5 to 1.0 ϫ 10 6 total kidney or spleen cells and 0.5 to 1.0 ϫ 10 5 of cultured cells using a FACSCalibur (Becton Dickinson, San Jose, CA) and analyzed data using Flowjo software (Tree Star, Palo Alto, CA).
Antibodies
We used the following Ab from eBioscience (San Diego, CA) for FACS analysis: FITC-conjugated anti-CD4 (L3T4), anti-CD8 (53-6.7), anti-B220 (RA3-6B2), and anti-CD45.2 (104); PE-conjugated anti-CD4, anti-CD45.2, anti-CD69 (H1.2F3), and anti-CD86 (GL1); PE-Cy5-conjugated anti-CD8 and anti-TCR-␤ chain (H57-597); and allophycocyanin-conjugated anti-CD4, anti-CD45.2, and anti-F4/80 (BM8). We used FITC-and allophycocyanin-conjugated anti-CD68 Ab (FA11; Serotec, Oxford, UK). We used purified rabbit anti-mouse CXCR3 Ab (Zymed, San Francisco, CA), purified goat anti-mouse CXCL9 Ab (R&D Systems, Minneapolis, MN), and rabbit anti-mouse CXCL10 Ab (PeproTech, Rocky Hill, NJ). The following isotype-specific Ab were used for controls: Rat-IgG2a (BR2a), rat-IgG2b (KLH/ G2b-1-2), and rabbit-IgG (eBioscience). As secondary PE-or allophycocyanin-conjugated Ab, we used goat anti-rabbit (Jackson ImmunoResearch Laboratories; West Grove, PA) and biotin-conjugated rabbit anti-goat Ab (Vector Laboratories, Burlingame, CA). To detect biotin-conjugated secondary Ab, we used streptavidin PE or allophycocyanin (Jackson ImmunoResearch Laboratories). We identified renal proximal tubules by binding of fluorescein-conjugated lotus lectin (Vector Laboratories). 49, 50 Histopathology We fixed kidneys in 10% formalin and prepared and stained paraffin sections with the periodic acid Schiff reagent. Slides were coded before grading the renal pathology.
MRL-Fas
lpr Mice.We evaluated renal (glomerular, tubular, interstitial, and perivascular) pathology on a scale of 0 (normal) to 3 (severe) as described previously. 45 
NSN. We evaluated CXCL9
Ϫ/Ϫ , CXCL10 Ϫ/Ϫ , CXCR3 Ϫ/Ϫ , and B6 kidneys for glomerular and tubular damage as described previously. 11 
Gross Pathology
We evaluated skin lesions monthly from 2 to 6 mo of age using a scoring system previously described. 10 
Immunohistochemistry
We stained cryostat-cut kidney sections for the presence of Mø with anti-CD68 Ab (FA-11; Serotec) and for T cells with anti-CD4 Ab (RM4-5), anti-CD8 Ab (53-6.7), and anti-B220 (RA3-6B2) rat antimouse Ab (Pharmingen, San Diego, CA) according to a previously described immunoperoxidase method. 51 To evaluate CXCL9 and CXCL10 expression in the kidney, we stained frozen sections with goat anti-mouse CXCL9 and rabbit anti-mouse CXCL10. 52 To determine the number of activated Mø in the kidney during NSN, we fixed frozen kidney sections in paraformaldehyde, stained them with rat anti-mouse TNF-␣-PE (MP6-XT22; eBioscience) and anti-CD68-FITC (FA-11; Serotec), and analyzed these sections using a fluorescence microscope. The frequency (%) of activated Mø was assessed by enumerating the number of CD68 ϩ TNF-␣ ϩ cells within the total number of Mø (CD68 ϩ ) in five high-power fields.
Renal Function
We assessed urine proteins semiquantitatively by dipstick analysis as described previously. 45 We measured blood urea nitrogen levels using a colorimetric analysis kit (Infinity; Thermo Electron, Melbourne, Australia) and serum creatinine using the creatinine reagent kit and Creatinine Analyzer 2 (Beckman Coulter, Galway, Ireland) according to the manufacturer's instructions.
Survival
We compared survival of the CXCL10 Ϫ/Ϫ MRL-Fas lpr and WT MRLFas lpr mice using similar numbers of males and females from birth to 10 mo of age.
Serum Anti-Sheep and Anti-Rabbit IgG Isotypes
We measured the levels of mouse anti-sheep IgG Ab (Sigma Chemical Co.) and anti-rabbit IgG (Jackson ImmunoResearch Laboratories) by ELISA using sera collected at day 14 during NSN as described previously. 53 We detected bound mouse anti-sheep/anti-rabbit IgG, IgG1, and IgG2b using peroxidase-conjugated rabbit anti-mouse IgG Ab (1:5000; Southern Biotechnology).
IgG Deposits within the Kidney
We evaluated IgG deposits within renal glomeruli as described previously. 54 We evaluated stained sections by scoring 20 glomeruli as either positive or negative and graded the amount (severity) of deposits in 20 positive glomeruli per specimen on a scale of 0 to 3 using multiple dilutions (1:3000, 1:4500, 1:6000, and 1:7500) of the detection Ab (fluorescein-conjugated goat anti-mouse IgG; MP Biomedicals, Aurora, OH). 40 
Statistical Analyses
The data are means Ϯ SEM and were analyzed by GraphPad Prism 4.0 (GraphPad, San Diego, CA). We used the nonparametric MannWhitney U test to determine differences among groups. Survival curves were compared and analyzed using the log-rank test.
